# Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen

> **NCT01042925** · PHASE1,PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 42 (actual)

## Conditions studied

- Breast Cancer
- Breast Neoplasms

## Interventions

- **DRUG:** XL147 (SAR245408)
- **BIOLOGICAL:** trastuzumab
- **DRUG:** paclitaxel

## Key facts

- **NCT ID:** NCT01042925
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2016-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01042925

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01042925, "Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01042925. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*